Tirofiban (Aggrastat ®)

Intravenous Dilution Guidelines

The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents

NS, D5W

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]

Total volume = 250 ml:
[12.5 mg (50ml)] [200 ml]
(Infusion rate: see comments)
-----
Total volume = 500 ml:
[25 mg (100ml)] [400 ml]
(Infusion rate: see comments)

Stability / Miscellaneous

Indications: In combination with heparin, treatment of acute coronary syndrome (unstable angina, non-Q wave MI), including patients undergoing PTCA or atherectomy.

Dosing: 0.4 mcg/kg/min for 30 min, followed by 0.1 mcg/kg/min. Therapy should continue through angiography and for 12-24hours after angioplasty or atherectomy.

Renal Adjustment:
(Note: Reduce dose by 50% if CRCL < 30 ml/min -- 0.2 mcg/kg/min x 30 minutes, then 0.05 mcg/kg/min.)

Hemodialysis:
USE WITH CAUTION.
Reduce dose by 50% (0.2 mcg/kg /min x 30 minutes, then 0.05 mcg/kg/min).

Supplied: 250 mcg/ml-50 ml vial (12.5 mg/50ml).

Calculation of rate: Loading dose (ml/hr) = 0.48 x weight(kg). Infuse for 30 minutes. Continuous infusion (ml/hr) = 0.12 x weight (kg) .

Most Patients

0.4 mcg/kg/min for 30 min, followed by 0.1 mcg/kg/min.

Severe Renal Impairment

Reduce dose by 50% (0.2 mcg/kg/min x 30 min, then 0.05 mcg/kg/min).

Patient Weight (kg)

30 minute Loading

Infusion Rate
(mL/hr)

Maintenance
Infusion
Rate (mL/hr)

30 minute Loading

Infusion Rate (mL/hr)

Maintenance
Infusion
Rate (mL/hr)

30-37

38-45

46-54

55-62

63-70

71-79

80-87

88-95

96-104

105-112

113-120

121-128

129-137

138-145

146-153

Source: [package insert]

Disclaimer

The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.